PURPOSE: To provide a carcinostatic agent containing a specific platinum complex as an active component.
CONSTITUTION: A compound of formula 1 (A is direct bond or -CH2-), e.g. cis- dichloro-trans-dihydroxo[1-(2-aminoethyl)pyrrolidine]platinum (IV) is used as an active component of the objective agent. The agent is administered in the form of an oral drug such as a solid preparation (e.g. tablet, pill, capsule, etc.) or liquid preparation (e.g. solution, suspension, etc.) or a parenteral drug such as injection, suppository, etc., at a dose of 200W400mg/kg daily for oral drug and 100W200mg/kg daily for parenteral drug. The compound of formula 1 used as an active component can be produced by reacting the compound of formula 2 with the compound of formula 3 in an aqueous solvent at 0W100°C for 1hrW4 days and reacting the resultant compound of formula 4 with hydrogen peroxide in an aqueous solvent at 0W120°C for 30minW5hr.
EFFECT: It has excellent anti-tumor activity and definitely weak bonding power to plasma protein compared with conventional platinum complex and CDDP, etc., and is useful as a carcinostatic agent.
MORIKAWA KAZUMI
ENDO KOICHI
| JPS61267595A | 1986-11-27 | |||
| JPS60184015A | 1985-09-19 | |||
| JPS60209595A | 1985-10-22 | |||
| JPS61229893A | 1986-10-14 | |||
| JPS60214795A | 1985-10-28 |